News about Global Pharma

FDA Inaugurates CDER Center for Clinical Trial Innovation (C3TI)

FDA's Center for Drug Evaluation and Research (CDER) has launched the CDER Center for Clinical Trial Innovation (C3TI).

Global Pharma | 16/04/2024 | By Aishwarya |  689

Caplin Steriles Receives USFDA Approval for Generic Ofloxacin Ophthalmic Solution

This approval marks the introduction of a generic therapeutic equivalent version of OCUFLOX Ophthalmic Solution by Allergan Inc.

Global Pharma | 16/04/2024 | By Abha |  824

Beckman Coulter Expands Hepatitis Testing Capabilities with New Assays on DxI 9000 Analyzer

Notably, Access anti-HCV, Access HBsAg, and Access HBsAg Confirmatory assays have recently obtained CE marks.

Global Pharma | 16/04/2024 | By Abha |  680

Athira Pharma Announces Appointment of Javier San Martin as Chief Medical Officer

Athira Pharma, Inc. has appointed Javier San Martin, MD, as Chief Medical Officer.

Global Pharma | 16/04/2024 | By Aishwarya |  879

MTPA Presents Healthcare Resource Utilization Data in RADICAVA ORS at AMCP 2024

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has recently presented one abstract on amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting.

Global Pharma | 16/04/2024 | By Aishwarya |  520

Neurvati Neurosciences Apoints Deborah Dunsire, MD, as Member and Chair of Company Board of Directors

Neurvati Neurosciences announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company's board of directors.

Global Pharma | 15/04/2024 | By Manvi |  800

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Viatris Inc. announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team.

Global Pharma | 15/04/2024 | By Manvi |  389

Kiora Receives Grant from CRF for Clinical Trial Endpoints for Inherited Retinal Diseases

Kiora Pharmaceuticals has secured grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients with profound blindness.

Global Pharma | 15/04/2024 | By Aishwarya |  319

Granules India Unit V Facility Completes US FDA Inspection with Zero 483 Observations

Granules India Ltd. has announced that the company’s Unit V facility has completed the US Food and Drug Administration (FDA) inspection between April 8-12, 2024, resulting in zero 483 observations.

Global Pharma | 15/04/2024 | By Aishwarya |  1085

FDA Approves New Administration Options for XCOPRI to Address Needs of Patients with Seizures

The newly approved administration options allow XCOPRI tablets to be crushed and mixed with water, providing patients with additional flexibility in medication administration.

Global Pharma | 15/04/2024 | By Abha |  490